the aid library

LIST OPTIONS

Filter

9050

Sort by:

Direction:

Download (597)

View PDF (2187)

Guidelines for Prevention and Control of Chikungunya Fever

World Health Organization, Regional Office South-East Asia (2009)

Download (153)

View PDF (393)

EFFECTIVENESS OF SHORTENED COURSE (≤ 3 DAYS) OF ANTIBIOTICS FOR TREATMENT OF ACUTE OTITIS MEDIA IN CHILDREN

Gulani, A. & Sachdev, H.P.S World Health Organisation (WHO) (2009) C_WHO

A systematic review of randomized controlled efficacy trials | REPORT - DEPARTMENT OF CHILD AND ADOLESCENT HEALTH AND DEVELOPMENT

Download (254)

View PDF (549)

Advocacy, communication & social mobilization (ACSM) for tuberculosis control (Handbook)

World Health Organization, Stop TB Partnership (2007) C_WHO

A Handbook for country programmes

Download (963)

View PDF (2447)

Inactivated poliovirus vaccine following oral poliovirus vaccine cessation

World Health Organization (2006)

Download (1697)

View PDF (7941)

Management of Waste from Injection Activities at District Level
recommended

World Health Organization (2006) C_WHO

Guidelines for District Health Managers

Download (266)

View PDF (298)

Руководство по программному лечению лекарственно-устойчивого туберкулеза

Департамент "Остановить туберкулез", ВОЗ World Health Organization (2006) C_WHO

Данное руководство содержит детальное описание стратегии диагностики и ведения пациентов с лекарственно-устойчивыми формами ТБ, прежде всего с туберкулезом с мн�... more

Download (386)

View PDF (508)

WHO Recommended Surveillance Standards Dengue Fever

World Health Organization (2000)

Download (856)

View PDF (1309)

WHO Recommended Surveillance Standards

World Health Organization (1999)

Second editon

Download (84)

View PDF (105)

Contraception within the context of adolescents’ sexual and reproductive lives - Zambia

World Health Organization WHO (2020) C_WHO

Country profile: Zambia

Download (10)

View PDF (12)

Action Plan for Implementation of Recommendations from the Evaluation of PAHO's Response to COVID-19

Pan American Health Organisation PAHO (2024) CC

An external team evaluated PAHO’s response to COVID-19 to provide an independent assessment of the Pan American Sanitary Bureau’s (PASB) performance regarding preparedness for and response to the COVID-19 pandemic. The evaluations’ final report culminates with eight recommendations for actions... more

Download (18)

View PDF (14)

Communicable and non-communicable diseases in Africa in 2021/22

World Health Organization Africa Region; WHO Africa World Health Organization Africa Region; WHO Africa (2023) C_WHO

This report is one of the first major products of the newly established Precision Public Health Metrics unit of the UCN cluster of the WHO Regional Office for Africa. The report presents national trends in communicable and non-communicable disease burden and control in the WHO African region. It tra... more

Download (29)

View PDF (12)

Risk communication and community engagement readiness and response toolkit: zika virus

World Health Organisation (WHO) (2024) C_WHO

Toolkit regarding Zika Virus

Download (42)

View PDF (32)

Mpox Multi-country external situation report n. 37

World Health Organisation (WHO) (2024) C_WHO

22 September 2024

Download (108)

View PDF (89)

Results Report - Programme budget 2020–2021 - Executive Summary

World Health Organization (WHO) World Health Organization (WHO) (2022) CC

This results report for the biennium 2020–2021 presents the progress towards the triple billion targets, outcomes and outputs, based on the GPW 13 results framework and indicators. It uses structured methodologies, both quantitative and qualitative, for measuring and analysing the achievements and... more

Download (184)

View PDF (145)

Clinical management of diphtheria: guideline

World Health Organization WHO (2024) C_WHO

WHO has published the first-ever guidance on the clinical management of diphtheria. The only previously available guidance was an operational protocol. The new guidance followed the rigorous process for developing guidance at WHO. It addresses the use of Diphtheria Antitoxin (DAT) in the treatmen... more

Download (133)

View PDF (135)

Tool for the accreditation of research ethics committees

Pan American Health Organization PAHO (2023) C_WHO

The ethical governance of research assumes the existence of a national entity (or subnational if applicable, according to the constitution of a country) in charge of supervising the research ethics committees (RECs) that review and monitor research with human beings. This supervision includes the ac... more

Download (106)

View PDF (106)

G2H2 Report on Financial Justice for Pandemic Prevention, Preparedness and Response

Geneva Global Health Hub (2022) CC

A year ago, the second Special Session of the World Health Assembly (WHASS) unanimously agreed to start a diplomatic process for a new binding instrument aimed at ensuring the international community is better prepared for the next health emergencies. The establishment of an Intergovernmental Negoti... more

Download (142)

View PDF (195)

Lao People’s Democratic Republic-WHO Country Cooperation Strategy 2024–2028

World Health Organization WHO (2023) C_WHO

This country cooperation strategy (CCS) outlines how the World Health Organization (WHO) will work with the Lao People’s Democratic Republic over the next five years (2024–2028), supporting the implementation of the five-year health sector development plans and the Health Sector Reform Strategy ...2021–2030 to attain the Sustainable Development Goals (SDGs) by 2030. The Lao People’s Democratic Republic experienced substantial economic growth in the 30 years prior to the coronavirus disease (COVID-19) pandemic, contributing to reduced poverty and significant progress toward the SDGs. However, the COVID-19 pandemic brought this development to a halt. It was anticipated that the COVID-19 recovery and the tremendous population growth in recent years would provide opportunities for a shift toward more sustainable and inclusive development in the years ahead. In 2023, however, the contrary was the case. Rural residents, including many ethnic minorities, continued to face marginalization because of limited access to education, health care and economic opportunities. Despite the challenges of COVID-19 and other disease outbreaks, the country has made significant improvements in health. Nonetheless, progress has been uneven and not everyone has benefited from these achievements. In the mountainous region, many people lack access to quality health care because of the unequal distribution of well-trained health-care workers. Preventable deaths due to poor-quality health care for children and newborns, infants and mothers remain a concern, as do communicable diseases such as sexually transmitted infections and tuberculosis. The increasing burden of noncommunicable diseases and the health impact of worsening climate change further heighten the need for strengthened and resilient health systems, which are at risk due to an underfunded health sector and weak economy. This CCS aims to address remaining and future challenges as well as health needs while creating an impact that is sustainable. It identifies three strategic priorities and nine deliverables (Table 1) to support the attainment of the national vision of Health for all by all, as articulated in the 9th Health Sector Development Plan 2021–2025. It contributes to the country’s goals to achieve universal health coverage, graduate from least developed country status by 2026 and attain SDGs by 2030. more

Download (247)

View PDF (332)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (211)

View PDF (187)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Management of Waste from Injection Activities at District Level recommended

Management of Waste from Injection Activities at District Level
recommended